Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | MMP2 | P08253 | 1/20 | 0.61 |
| ▸ | MMP8 | P22894 | 1/20 | 0.61 |
| ▸ | KDR | P35968 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3390183 | 0.90 | MMP2 (0.65) | NPC1MMP2MMP8KDRKMT2A | |
| SCHEMBL15401573 | 0.83 | MMP2 (0.76) | NPC1MMP2MMP8KDRKMT2A | |
| SCHEMBL28247801 | 0.82 | NPC1 (0.80) | NPC1MMP2MMP8KMT2APOLB | |
| SCHEMBL24993421 | 0.78 | MMP2 (0.80) | NPC1MMP2MMP8KDRKMT2A | |
| SCHEMBL16458931 | 0.78 | MMP2 (0.86) | NPC1MMP2MMP8KDRKMT2A | |
| SCHEMBL9370361 | 0.78 | FAAH (0.61) | NPC1LMNAMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL3396188 | 0.77 | SLC27A1 (0.64) | KMT2APOLBMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL30772150 | 0.77 | MMP2 (0.86) | NPC1MMP2MMP8KMT2ALMNA | |
| SCHEMBL3394204 | 0.76 | SMN1; SMN2 (0.64) | NPC1KMT2APOLBLMNAMEN1 | |
| SCHEMBL3394398 | 0.76 | KCNA5 (0.65) | KDRKMT2ALMNAMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029681-A1 | HETEROCYCLIC COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2010-02-04 | — | — | US | claimed |
| US-20100029681-A1 | HETEROCYCLIC COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2010-02-04 | — | — | US | disclosed |
| US-20100029681-A1 | HETEROCYCLIC COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2010-02-04 | — | — | US | disclosed |
| WO-2007137417-A1 | HETEROCYCLIC COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029681-A1 | HETEROCYCLIC COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1B, CACNA1C, CACNA1I | NPC1 1815/4885MMP2 3074/4885MMP8 3028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.